Background
==========

Over the recent years the cloning of genes involved in complex diseases such as cancer as well as the development of new high throughput techniques like single nucleotide polymorphism (SNP) arrays has made enormous progress. This resulted in more than 100 000 human genetic variations which have been described in various genes associated with a wide variety of diseases ([@B1; @B2; @B3]). Somatic variations in cancer are used in clinical studies and molecular pathology to characterize tumor types, to improve the best suited treatment choice, and to predict response to treatment. Thus, mutation analysis can play an important role in drug discovery and drug development. Identification of genetic variants will yield new drug targets and biomarkers.

Cancer, as a disease of genome alterations, arises through the sporadic acquisition of multiple somatic variations ([@B4]). However, not all mutations contribute equally to the cancer type in which they are found. The proportion of mutations causally implicated in cancer is still unknown especially due to the high number of variations between different tumors ([@B5; @B6; @B7; @B8; @B9]) Although the number of unique variations for each cancer genome can be very high ([@B10],[@B11]), only a few somatic variations will be critical for the development of the tumor. These causative variations, the so-called 'drivers', are emerging because of selective pressure during tumorigenesis, whereas many mutations are only incidental or caused by genome instabilities, so-called 'passengers' ([@B12]). The differentiation of disease causing driver mutations from the passenger variations is a challenge for mutation analysis ([@B13]).

Usefulness of mutation analysis
===============================

Analysis of mutations is useful in many ways: the study of cancer-prone DNA repair diseases (Xeroderma pigmentosum, Ataxia telangiectasia, Fanconi's anemia, Bloom's syndrome and others) has given valuable insights in the type and function of genes responsible for maintaining DNA integrity ([@B14; @B15; @B16; @B17; @B18]). Mutation analysis can help to predict the risk for developing certain types of cancer, *BRCA1* and *BRCA2* (increased breast cancer risk) ([@B19]) and *APC* (increased risk for colon cancer) ([@B20]) being among the best known so far.

Mutations can also influence the response of patients to cancer drugs, e.g. the *KRAS* ([@B21],[@B22]) or *BRAF* ([@B23],[@B24]) mutations. The presence of certain mutations can also influence progression free or overall survival rates of patients ([@B22],[@B25]).

Germline versus somatic mutations
=================================

In general, mutations can be grouped into two different categories: germline and somatic. *Germline mutations* are variations found in all cells of an organism including germ line cells. They play an important role in evolution by giving every human its genetic individuality (see SNPs) but also give a rise to hereditary diseases like sickle-cell anemia or phenylketonuria. Germline mutations can also lead to increased risk for developing cancer, like *BRCA1* and *BRCA2* gene mutations which are associated with an increased risk for breast and ovarian cancer ([@B26; @B27; @B28]). Other examples of familial cancer syndromes include von Hippel--Lindau syndrome (caused by mutations in *VHL*) ([@B29]), Peutz--Jeghers syndrome (caused by mutations in *LKB1*) ([@B30]) and Li--Fraumeni syndrome (caused by mutations in *TP53*) ([@B31]).

Detection of germline mutations with current technologies is state of the art but time-consuming. Usually a large amount of genetic material of good quality can be extracted from blood cells. However, in addition to the mutation detection, the differentiation of disease causing and neutral germline mutations having no effect on the phenotype is an important but non-trivial task. Currently, no generally applicable solution for this problem exists and this question often remains unsolved.

*Somatic mutations* are not inherited but acquired during lifetime in somatic cells of an organism and might cause tissue specific tumors. An important problem with somatic mutations is the difficulty of their detection. Tumor samples can be very heterogeneous and are very often 'contaminated' with normal cells, such as stromal cells. However, since somatic mutations are identified through a comparison of a tumor sample with a normal sample of the same organism the identification of the mutation is unambiguous. Also for somatic mutations the differentiation between drivers and passengers is an important but still unsolved problem. In contrast to germline mutations however, all somatic mutations are tumor associated. Therefore, all non-silent somatic mutations are potential candidates for biomarker development.

Mutation types
==============

Genome alterations are typically classified by the mutation type. The different databases characterize all variations first by the effect on the nucleotide sequence: *deletions, insertions* and *single nucleotide variations*. Mutations occurring in the coding region of a gene can also be classified by their effect on the amino acid sequence. A variation of the coding sequence without any change of the amino acid sequence of the protein is called s*ilent* mutation. Single nucleotide mutations causing the substitution of a different amino acid are called *missense* mutation. A *frameshift* mutation is an insertion or deletion in the coding sequence which changes the reading frame resulting in a different translation of the subsequent sequence. *Nonsense* mutations generate a premature stop codon and often a non-functional truncated protein product.

SNPs versus germline mutations
==============================

Single nucleotide germline mutations and SNP are often used as synonyms, since both describe variations of single nucleotides, which are inherited and not tumor-associated per se. However, concerning the databases presented here these synonyms are used in two different meanings: SNPs as presented in public databases like dbSNP ([@B32],[@B33]) or HapMap ([@B34]) are germline variations for which at most population frequencies are known. In literature it is usually assumed that the variation should be found in more than 1% of the population in order to be called a SNP. Such information is very useful for biomarker development since it describes the prevalence of the mutation in different populations. However, it is normally not possible to get additional information (like gender, age, or disease status) on the individuals having the SNP, only the population a person belongs to is given. Since it is not known if the information comes from a tumor or normal sample, a correlation between diseases and SNPs cannot be calculated.

In contrast, germline mutations presented in cancer or disease mutation databases like 'The Cancer Genome Atlas (TCGA)' ([@B35]) are usually connected with additional sample information like patient gender, age, histology or tissue. Germline mutations are found in the normal as well as the tumor sample. Hence, the sample information allows for further analyses of associations between germline mutations and diseases.

Standardization efforts
=======================

A standard problem occurring in every field where huge amounts of data are generated is standardization. Without standardization the task to identify and integrate the data is very complicated, laborious, error-prone and time-consuming. Although databases may have different scope and aims it is important to standardize content and annotation. The Human Genome Variation Society (HGVS) has proposed a recommendation for the nomenclature of genetic variations and content of mutation databases and scientific publications ([@B36]). This naming of mutations has now become widely accepted. Some journals (e.g. Human Mutation) already accept only publications with mutation notation following the HGVS proposed recommendations. If more publishers should follow this trend it would have a very positive effect on the usability of mutation databases including an increase of the quality and amount of their content.

HGVS and members have published number of recommendations e.g. for the collection of somatic mutations, sharing data, etc. There are also projects at European Bioinformatics Institute (EBI) and National Center for Biotechnology Information (NCBI) to develop reference sequences, locus reference genomics (LRGs) (<http://www.lrg-sequence.org>) and RefSeqGenes (<http://www.ncbi.nlm.nih.gov/projects/RefSeq/RSG/>), respectively. In addition, the Gen2Phen (<http://www.gen2phen.org>) project works on data models and standards for a number of aspects related to variation data description, storage and integration in databases.

Except for the already widely accepted naming recommendations of mutations by the HGVS, a promising standardization effort for integrating all cancer genome data is still missing.

Structure and accessibility
===========================

Historically, mutations and variations in human have been reported only in the published literature. Mutation descriptions were often not precise, no standard notation existed, and the sequence of the reference gene under study was almost never indicated. To this end a sophisticated mutation analysis was mostly unfeasible. However, with the explosion of large-scale cancer genome sequencing ([@B35],[@B37; @B38; @B39; @B40]) more and more information on genetic variations has been captured over the last years in publicly available databases that can be used by clinicians or scientists as a research tool. These databases are widespread and their scope, format and content can be very different. Current data related to somatic mutations is mostly buried in journals or scattered between several locus-specific databases (LSDBs) and general databases that have no or very limited connections between them.

Only a few large public resources exist that comprehensively compile data on somatic gene alterations in cancer: International Agency for Research on Cancer (IARC) TP53 Database ([@B41]), Catalog of Somatic Mutations in Cancer (COSMIC) ([@B42]), TCGA ([@B35]), Roche Cancer Genome Database (RCGDB) and Human Gene Mutation Database (HGMD®) ([@B43]).

The LSDBs often originate as loosely organized compilation of data. Since no standard system similar to the HGVS recommendation for mutation notation has yet been established, the presentation of the data in LSDBs varies enormously. The data is mostly presented in flat files, plain text databases, or Microsoft Excel spreadsheets making it easy to collect and store the information, but nearly impossible to search or retrieve specific data. More ambitious databases use open source database management software (DBMS)---like MySQL or PostgreSQL---whereas only a minority of curators use specialized software such as the UMD ([@B44]), the Mutation Storage and Retrieval Program (MuStaR) ([@B45]), or the Leiden Open Source Variation Database (LOVD) ([@B46]). The use of such relational DBMSs allows to specify complex queries and specific analyses of customized subsets of the database.

Cancer variation databases
==========================

Currently, the best-known publicly available primary database on somatic mutations in human cancer is the 'COSMIC'([@B42]) hosted at the Wellcome Trust Sanger institute in Cambridge. The data is gathered from scientific publications and genome-wide screens from the Cancer Genome Project (CGP) at the same institute. The project has been continuously updated and improved for over 9 years and currently contains more than 108 773 mutations in \>13 500 different genes observed in over 449 676 different tumor samples. The curation process in COSMIC is largely manual resulting in a very high quality of the data. For each mutation all details on the sample like patient age, gender, histology and tissue are available. COSMIC uses its own internal classification system to provide tissue and histology consistency within the database and to reduce redundancy. All tissue and histology information from scientific publications is translated using this classification system. In addition, for each study the project offers the information which genes where actually screened, since published studies often focus on mutation hot spots, for example *KRAS* ([@B47]), *BRAF* ([@B48]) or *TP53* ([@B49]). This information enables frequency data to be calculated for mutations in various genes and different cancer types. COSMIC offers also somatic mutations found in cell-lines including the NCI-60 ([@B50]). The website of COSMIC has a clear structure and is easy to use. The interface allows to browse by gene, or search by phenotype. Summary information on mutation counts and frequencies are presented graphically for a better understanding. In addition, all information can be downloaded as txt files, or as an Oracle dump file.

Another large mutation data source is 'TCGA' ([@B35]), a project at the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). The main goal of TCGA is to understand the molecular basis of cancer through the application of genome analysis techniques, including large-scale genome sequencing and SNP analysis. For each patient a whole genome analysis of a normal, a tumor and control samples (a second normal and tumor sample as control) is performed enabling researchers to distinguish between somatic and germline mutations. All mutations found are publicly available in a special Mutation Analysis file Format (MAF) and can be downloaded via the TCGA Data Portal. This portal contains all TCGA data concerning to clinical information associated with tumors and human subjects, genomic characterization, and high-throughput sequencing analysis of the tumor genomes. However, no advanced search interface or graphical visualization of the mutation data is available. In the starting phase the project focused on only two cancer types: brain cancer (glioblastoma multiforme) and ovarian serous adenocarcinoma. After the pilot phase, which was completed in 2009, TCGA matured to a full project and is now dealing with more than 20 types of cancer.

Another concept focusing on the integration of heterogeneous mutation data sources is pursued by the RCGDB ([@B51]), developed at Roche Pharma Research. The freely available warehouse system integrates somatic and germline mutations gathered by manual curation from scientific publications and public cancer mutation databases (COSMIC, TCGA, etc.). In addition, these mutations are enriched by SNP data from the HapMap ([@B34]) project. Updates are provided on a regular basis depending on the update frequency of the external data sources (approximately every 3 months). Access to the RCGDB is offered via a publicly available web interface. A major aspect in designing the user interface was that users should be able to search and view mutations in an intuitive and straight-forward manner, without having to understand the architectural details of the warehouse system. Therefore, the database offers a Google-like web interface to search for cancer genome information on a single gene, sample or cell-line, and on multiple genes, samples or cell-lines. As a special feature the search is supported by an auto-suggestion functionality allowing to search by NCBI GeneIDs, names, or synonyms.

The HGMD® ([@B43]) at the Institute of Medical Genetics in Cardiff is a commercial mutation database providing information on somatic and germline mutations. Furthermore, the database offers a less up-to-date public version which is freely available only to registered users from academic institutions or non-profit organizations, respectively. The data is gathered from scientific publications and from publicly available LSDBs. The project claims to include all mutations causing or associated with human inherited disease, plus disease-associated/functional polymorphisms reported in the literature. Currently, HGMD provides information on 96 631 mutations in 3611 genes under the professional license and 69 660 mutation in 2572 genes in the public version of the database. The website of HGMD allows to search by gene, publication or mutation id and presents the results in a table view. A downloadable version of HGMD is only available under the professional license.

In addition to multi-gene LSDBs, various single-gene LSDBs are publicly available. The largest and best-known single-gene LSDB is the *TP53 mutation database* from the IARC ([@B41]), with all TP53 gene variations identified in human populations and tumor samples since 1989. The database contains information on somatic as well as germline mutations of TP53 in patient samples, human cell-lines, and mouse models. This data is compiled from the peer-reviewed literature and from generalist databases. The website offers different sophisticated interfaces for searching and mining the database by multiple criteria. Furthermore, all information can be downloaded in tab-delimited txt-files. A large number of other single gene databases exists like the *L1CAM mutation database* from the university of Groningen ([@B52]) containing single gene somatic mutations. Most of these LSDBs are small containing mostly \<500 variants.

For a detailed list of cancer mutation databases see [Table 1](#T1){ref-type="table"}. Table 1.Cancer variation database: a list of available cancer variation databases including web linksDatabaseURLGene(s)Mutation typeRemarkBLMbase<http://bioinf.uta.fi/BLMbase>BLMGermlineCASP10base<http://bioinf.uta.fi/CASP10base>CASP10GermlineCASP8base<http://bioinf.uta.fi/CASP8base>CASP8GermlineCatalog of Somatic Mutations in Cancer (COSMIC)<http://www.sanger.ac.uk/genetics/CGP/cosmic/>\>13 500SomaticFanconi Anemia Mutation Database<http://www.rockefeller.edu/fanconi/mutate/>FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, FANCNGenetic Alterations in Cancer DB (GAC)<http://www.niehs.nih.gov/research/resources/databases/gac/>32 cancer genesSomatic, germlineHNPCC database<http://www.insight-group.org/>APC, EPCAM, MUTYH, MSH2, MSH6, MLH1, MLH3, PMS1, PMS2Human Genome Variation and Genotype/Phenotype Database (HGVbaseG2 P)<http://www.hgvbaseg2p.org/index>GermlineIARC TP53 database<http://www-p53.iarc.fr/>TP53Somatic, germlineInternational HapMap Project<http://www.hapmap.org/>SNPKinMutBase<http://bioinf.uta.fi/KinMutBase/>Protein kinasesGermlineLOVD-ATM<http://www.LOVD.nl/ATM>ATMGermlineUses Leiden Open Variation DatabaseLOVD-B3GALTL<http://www.LOVD.nl/B3GALTL>B3GALTLGermlineUses Leiden Open Variation DatabaseLOVD-BRCA2<http://www.LOVD.nl/BRCA2>BRCA2GermlineUses Leiden Open Variation DatabaseLOVD-FANCA<http://www.LOVD.nl/FANCA>FANCAGermlineUses Leiden Open Variation DatabaseLOVD-FANCB<http://www.LOVD.nl/FANCB>FANCBGermlineUses Leiden Open Variation DatabaseLOVD-FANCC<http://www.LOVD.nl/FANCC>FANCCGermlineUses Leiden Open Variation DatabaseLOVD-FANCD2<http://www.LOVD.nl/FANCD2>FANCD2GermlineUses Leiden Open Variation DatabaseLOVD-FANCE<http://www.LOVD.nl/FANCE>FANCEGermlineUses Leiden Open Variation DatabaseLOVD-FANCF<http://www.LOVD.nl/FANCF>FANCFGermlineUses Leiden Open Variation DatabaseLOVD-FANCG<http://www.LOVD.nl/FANCG>FANCGGermlineUses Leiden Open Variation DatabaseLOVD-FANCL<http://www.LOVD.nl/FANCL>FANCLGermlineUses Leiden Open Variation DatabaseLOVD-MUTYH<http://www.LOVD.nl/MUTYH>MUTYHGermlineUses Leiden Open Variation DatabaseLOVD-NOTCH3<http://www.LOVD.nl/NOTCH3>NOTCH3GermlineUses Leiden Open Variation DatabaseLOVD-NROB1<http://www.LOVD.nl/NROB1>NROB1GermlineUses Leiden Open Variation DatabaseLOVD-OTC<http://www.LOVD.nl/OTC>OTCGermlineUses Leiden Open Variation DatabaseLOVD-TSC1<http://www.LOVD.nl/TSC1>TSC1GermlineUses Leiden Open Variation DatabaseLOVD-TSC2<http://www.LOVD.nl/TSC2>TSC2GermlineUses Leiden Open Variation DatabaseMDL EGFR Mutation Database<http://www.egfr.org/>EGFRSomatic, germlineMismatch Repair Genes Variant Database<http://www.med.mun.ca/mmrvariants/>MSH2,MSH6,MLH1,PMS2GermlineNCBI dbSNP<http://www.ncbi.nlm.nih.gov/projects/SNP/>SNPOnline Mendelian Inheritance in Man (OMIM)<http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim>All genesGermlinePTCH Mutation Database<http://www.cybergene.se/PTCH/>PTCHSomatic, germlineRoche Cancer Genome Database (RCGDB)<http://rcgdb.bioinf.uni-sb.de/MutomeWeb>\>10 000Somatic, SNPThe Cancer Genome Atlas (TCGA)<http://cancergenome.nih.gov/>\>400Somatic, germlineLogin for TCGA Data Portal necessary, more disease to comeThe Human Gene Mutation Database (HGMD)<http://www.hgmd.cf.ac.uk/ac/index.php>2572Somatic, germlineCommercial license: 3611 genesThe TP53 database<http://p53.free.fr/>TP53Somatic, germlineTSH Receptor mutation database<http://www.uni-leipzig.de/innere/tsh/>TSHRSomatic, germlineUMD-APC<http://www.umd.be/APC/>APCGermlineUMD-BRCA1<http://www.umd.be/BRCA1/>BRCA1GermlineRestricted accessUMD-BRCA2<http://www.umd.be/BRCA2/>BRCA2GermlineRestricted accessUMD-MEN1<http://www.umd.be/MEN1/>MEN1GermlineUMD-VHL<http://www.umd.be/VHL/>VHLGermlineUML-TGFBR2<http://194.167.35.228/TGFBR2/>TGFBR2GermlineUniversity of Groningen L1CAM Mutation DB<http://www.l1cammutationdatabase.info/>L1CAMSomaticWASbase<http://bioinf.uta.fi/WASbase>WASPGermlineWerner Syndrome Mutational Database<http://www.pathology.washington.edu/research/werner/database/>WRNGermline[^1]

Disease variation databases
===========================

In addition to the Cancer variation database a large number of publicly available databases focuses on disease specific variations. An overview on such disease variation databases can be found in [Table 2](#T2){ref-type="table"}. Table 2.Disease variation databases: a list of available disease variation databases including web linksDatabaseURLGene(s)DiseasesRemarkADAbase<http://bioinf.uta.fi/ADAbase>ADAAdenosine deaminase deficiencyAICDAbase<http://bioinf.uta.fi/AICDAbase>AICDANon-X-linked hyper-IgM syndromeAIREbase<http://bioinf.uta.fi/AIREbase>AIREAutoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy (APECED)Albinism Database (CHS)<http://albinismdb.med.umn.edu/chs1mut.html>LYSTChediak--Higashi SyndromeAlbinism Database (HPS2)<http://albinismdb.med.umn.edu/hps2mut.htm>AP3B1Hermansky--Pudlak syndrome 2ALPSbase (II)<http://research.nhgri.nih.gov/ALPS/alpsII_mut.shtml>CASP10Autoimmune lymphoproliferative syndrome, type IIALPSbase (Ia)<http://research.nhgri.nih.gov/ALPS/alpsIa_mut.shtml>FASAutoimmune lymphoproliferative syndrome, type IaAP3B1base<http://bioinf.uta.fi/AP3B1base>AP3B1Hermansky--Pudlak syndrome 2BIRC4base<http://bioinf.uta.fi/BIRC4base>BIRC4X-linked lymphoproliferative syndromeBLMbase<http://bioinf.uta.fi/BLMbase>BLMBloom syndromeBLNKbase<http://bioinf.uta.fi/BLNKbase>BLNKBLNK deficiencyBTKbase<http://bioinf.uta.fi/BTKbase>BTKX-linked agammaglobulinemia (XLA)C1QAbase<http://bioinf.uta.fi/C1QAbase>C1QAC1q α polypeptide deficiencyC1QBbase<http://bioinf.uta.fi/C1QBbase>C1QBC1q β polypeptide deficiencyC1QCbase<http://bioinf.uta.fi/C1QCbase>C1QCC1q γ-polypeptide deficiencyC1Sbase<http://bioinf.uta.fi/C1Sbase>C1 SC1 s deficiencyC2base<http://bioinf.uta.fi/C2base>C2C2 deficiencyC3base<http://bioinf.uta.fi/C3base>C3C3 deficiencyC5base<http://bioinf.uta.fi/C5base>C5C5 deficiencyC6base<http://bioinf.uta.fi/C6base>C6C6 deficiencyC7base<http://bioinf.uta.fi/C7base>C7C7 deficiencyC8Bbase<http://bioinf.uta.fi/C8Bbase>C8BC8B deficiencyC9base<http://bioinf.uta.fi/C9base>C9C9 deficiencyCA2base<http://bioinf.uta.fi/CA2base>CA2Osteopetrosis with renal tubular acidosisCASP10base<http://bioinf.uta.fi/CASP10base>CASP10Autoimmune lymphoproliferative syndrome, type IICASP8base<http://bioinf.uta.fi/CASP8base>CASP8Caspase 8 deficiencyCatalogue of Somatic Mutations in Cancer (COSMIC)<http://www.sanger.ac.uk/genetics/CGP/cosmic/>\>13 500multiple tissues and histologiesCD19base<http://bioinf.uta.fi/CD19base>CD19CD19 deficiencyCD247base<http://bioinf.uta.fi/CD247base>CD247CD3ζ deficiencyCD3Dbase<http://bioinf.uta.fi/CD3Dbase>CD3DCD3δ deficiencyCD3Ebase<http://bioinf.uta.fi/CD3Ebase>CD3 ECD3ε deficiencyCD3Gbase<http://bioinf.uta.fi/CD3Gbase>CD3 GCD3γ deficiencyCD40base<http://bioinf.uta.fi/CD40base>CD40CD40 deficiencyCD40Lbase<http://bioinf.uta.fi/CD40Lbase>CD40 LX-linked Hyper-IgM syndrome (XHIM)CD55base<http://bioinf.uta.fi/CD55base>CD55Decay-accelerating factor (CD55) deficiencyCD59base<http://bioinf.uta.fi/CD59base>CD59CD59 deficiencyCD79Abase<http://bioinf.uta.fi/CD79Abase>CD79 AIgα deficiencyCD79Bbase<http://bioinf.uta.fi/CD79Bbase>CD79BIgβ deficiencyCD8Abase<http://bioinf.uta.fi/CD8Abase>CD8 ACD8α deficiencyCEBPEbase<http://bioinf.uta.fi/CEBPEbase>CEBPENeutrophil-specific granule deficiencyCFDbase<http://bioinf.uta.fi/CFDbase>CFDFactor D deficiencyCFHbase<http://bioinf.uta.fi/CFHbase>CFHFactor H deficiencyCFIbase<http://bioinf.uta.fi/CFIbase>CFIComplement factor I deficiencyCFPbase<http://bioinf.uta.fi/CFPbase>CFPProperdin deficiencyCIITAbase<http://bioinf.uta.fi/CIITAbase>CIITAMHCII transactivating protein deficiencyCLCN7base<http://bioinf.uta.fi/CLCN7base>CLCN7Autosomal dominant osteopetrosis, type 2CTSCbase<http://bioinf.uta.fi/CTSCbase>CTSCPapillon-Lefevre syndromeCXCR4base<http://bioinf.uta.fi/CXCR4base>CXCR4WHIM syndromeCYBAbase<http://bioinf.uta.fi/CYBAbase>CYBAAutosomal recessive p22phox deficiencyCYBBbase<http://bioinf.uta.fi/CYBBbase>CYBBX-linked chronic granulomatous disease (XCGD)DCLRE1Cbase<http://bioinf.uta.fi/DCLRE1Cbase>DCLRE1 CArtemis deficiencyDKC1base<http://bioinf.uta.fi/DKC1base>DKC1Hoyeraal-Hreidarsson syndromeDNMT3Bbase<http://bioinf.uta.fi/DNMT3Bbase>DNMT3BICF syndromeELA2base<http://bioinf.uta.fi/ELA2base>ELA2Cyclic neutropenia; Congenital neutropeniaF12base<http://bioinf.uta.fi/F12base>F12Hereditary angioedema type IIIFanconi Anemia Mutation Database<http://www.rockefeller.edu/fanconi/mutate/jumpa.html>FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCLFanconi anemiaFASLGbase<http://bioinf.uta.fi/FASLGbase>FASLGAutoimmune lymphoproliferative syndrome, type 1B (ALPS1B)FCGR1Abase<http://bioinf.uta.fi/FCGR1Abase>FCGR1 ACD64 deficiencyFCGR3Abase<http://bioinf.uta.fi/FCGR3Abase>FCGR3 ANatural killer cell deficiencyFH aHUS Mutation Database<http://www.fh-hus.org/>CFHHemolytic uraemic syndrome (HUS)FOXN1base<http://bioinf.uta.fi/FOXN1base>FOXN1T-cell immunodeficiency, congenital alopecia, and nail dystrophyFOXP3base<http://bioinf.uta.fi/FOXP3base>FOXP3Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked; IPEXGFI1base<http://bioinf.uta.fi/GFI1base>GFI1Severe congenital neutropenia (SCN); Nonimmune chronic idiopathic neutropenia of adults (NI-CINA)HAEdb<http://hae.enzim.hu/>SERPING1Hereditary angioedemaHAX1base<http://bioinf.uta.fi/HAX1base>HAX1Severe congenital neutropenia (Kostmann disease)ICOSbase<http://bioinf.uta.fi/ICOSbase>ICOSICOS deficiencyIFNGR1base<http://bioinf.uta.fi/IFNGR1base>IFNGR1IFNγ1-receptor deficiencyIFNGR2base<http://bioinf.uta.fi/IFNGR2base>IFNGR2IFNγ2-receptor deficiencyIGHG2base<http://bioinf.uta.fi/IGHG2base>IGHG2IgG2 deficiencyIGHMbase<http://bioinf.uta.fi/IGHMbase>IGHMμ heavy chain deficiencyIGLL1base<http://bioinf.uta.fi/IGLL1base>IGLL1λ5surrogate light-chain deficiencyIKBKGbase<http://bioinf.uta.fi/IKBKGbase>IKBKGNemo deficiencyIL12Bbase<http://bioinf.uta.fi/IL12Bbase>IL12BInterleukin-12 (IL12) p40 deficiencyIL12RB1base<http://bioinf.uta.fi/IL12RB1base>IL12RB1Interleukin-12 receptor β1 deficiencyIL2RAbase<http://bioinf.uta.fi/IL2RAbase>IL2RAInterleukin-2 receptor α deficiencyIL2RGbase<http://research.nhgri.nih.gov/scid/>IL2RGX-linked SCIDIL7Rbase<http://bioinf.uta.fi/IL7Rbase>IL7 RInterleukin-7 receptor α deficiencyInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>LPIN2Majeed syndromeInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>MEFVFamilial Mediterranean feverInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>MVKHyper IgD Syndrome and periodic feverInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>NLRP3Familial cold autoinflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurological cutaneous and articular syndromeInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>NLRP7Recurrent Hydatidiform moles and reproductive wastageInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>NOD2Blau syndrome, Chrohn\'s disease, early onset sarcoidosisInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>PSTPIP1Pyogenic sterile arthritis, pyoderma gangrenosum and acne syndromeInfevers<http://fmf.igh.cnrs.fr/ISSAID/infevers/>TNFRSF1 ATumor necrosis factor receptor-associated periodic syndromeIRAK4base<http://bioinf.uta.fi/IRAK4base>IRAK4IRAK4 deficiencyITGB2base<http://bioinf.uta.fi/ITGB2base>ITGB2Leukocyte adhesion deficiency I (LAD-I)JAK3base<http://bioinf.uta.fi/JAK3base>JAK3Jak3 deficiencyLIG1base<http://bioinf.uta.fi/LIG1base>LIG1DNA ligase I deficiencyLIG4base<http://bioinf.uta.fi/LIG4base>LIG4LIG4 syndromeLRRC8Abase<http://bioinf.uta.fi/LRRC8Abase>LRRC8 ANon-Bruton type autosomal dominant agammaglobulinemiaLYSTbase<http://bioinf.uta.fi/LYSTbase>LYSTChediak--Higashi syndromeMAPBPIPbase<http://bioinf.uta.fi/MAPBPIPbase>MAPBPIPEndosomal adaptor protein p14 deficiencyMASP2base<http://bioinf.uta.fi/MASP2base>MASP2MASP2 deficiencyMLPHbase<http://bioinf.uta.fi/MLPHbase>MLPHGriscelli syndrome, type 3 (GS3)MPObase<http://bioinf.uta.fi/MPObase>MPOMyeloperoxidase deficiencyMRE11Abase<http://bioinf.uta.fi/MRE11Abase>MRE11 AAtaxia-telangiectasia-like disorder (ATLD)Mutation Database - Papillon Lefevre Syndrome<http://www.genetics.pitt.edu/mutation/pls/>CTSCPapillon Lefevre syndromeMYO5Abase<http://bioinf.uta.fi/MYO5Abase>MYO5 AGriscelli syndrome, type 1 (GS1)NCF1base<http://bioinf.uta.fi/NCF1base>NCF1Autosomal recessive p47phox deficiencyNCF2base<http://bioinf.uta.fi/NCF2base>NCF2Autosomal recessive p67phox deficiencyNFKBIAbase<http://bioinf.uta.fi/NFKBIAbase>NFKBIAAutosomal dominant anhidrotic ectodermal dysplasia and T-cell immunodeficiencyNHEJ1base<http://bioinf.uta.fi/NHEJ1base>NHEJ1Combined immunodeficiency (CID) associated with microcephaly and increased cellular sensitivity to IRNPbase<http://bioinf.uta.fi/Npbase>NPPNP deficiencyNRASbase<http://bioinf.uta.fi/NRASbase>NRASAutoimmune lymphoproliferative syndrome type IVORAI1base<http://bioinf.uta.fi/ORAI1base>ORAI1Severe combined immunodeficiencyOSTM1base<http://bioinf.uta.fi/OSTM1base>OSTM1Autosomal recessive osteopetrosisPIK3R1base<http://bioinf.uta.fi/PIK3R1base>PIK3R1Pathogenic mutations in the p85α SH2 domainPRF1base<http://bioinf.uta.fi/PRF1base>PRF1Familial haemophagocytic lymphohistiocytosis, type II (FHL2)PTPN11base<http://bioinf.uta.fi/PTPN11base>PTPN11Pathogenic mutations in the SHP-2 SH2 domainPTPRCbase<http://bioinf.uta.fi/PTPRCbase>PTPRCCD45 deficiencyRAB27Abase<http://bioinf.uta.fi/RAB27Abase>RAB27 AGriscelli syndrome, type 2 (GS2)RAC2base<http://bioinf.uta.fi/RAC2base>RAC2Neutrophil immunodeficiency syndromeRAG1base<http://bioinf.uta.fi/RAG1base>RAG1RAG1 deficiencyRAG2base<http://bioinf.uta.fi/RAG2base>RAG2RAG2 deficiencyRASA1base<http://bioinf.uta.fi/RASA1base>RASA1Pathogenic mutations in the RasGAP SH2 domainRASGRP2base<http://bioinf.uta.fi/RASGRP2base>RASGRP2Leukocyte adhesion deficiency IIIRFX5base<http://bioinf.uta.fi/RFX5base>RFX5MHCII promoter X box regulatory factor 5 deficiencyRFXANKbase<http://bioinf.uta.fi/RFXANKbase>RFXANKAnkyrin repeat containing regulatory factor X-associated protein deficiencyRFXAPbase<http://bioinf.uta.fi/RFXAPbase>RFXAPRegulatory factor X-associated protein deficiencyRoche Cancer Genome Database (RCGDB)<http://rcgdb.bioinf.uni-sb.de/MutomeWeb>\>10 000multiple tissues and histologiesSBDSbase<http://bioinf.uta.fi/SBDSbase>SBDSShwachman--Diamond syndromeSERPING1base<http://bioinf.uta.fi/SERPING1base>SERPING1Hereditary angioedemaSH2base<http://bioinf.uta.fi/SH2base>SH2Pathogenic SH2 domain mutationsSH2D1Abase<http://bioinf.uta.fi/SH2D1Abase>SH2D1 AX-linked lymphoproliferative syndrome (XLP)SLC35C1base<http://bioinf.uta.fi/SLC35C1base>SLC35C1Leukocyte adhesion deficiency I I (LAD-II)SMARCAL1base<http://bioinf.uta.fi/SMARCAL1base>SMARCAL1Schimke immuno-osseous dysplasiaSP110base<http://bioinf.uta.fi/SP110base>SP110Hepatic veno-occlusive disease with immunodeficiency syndrome (VODI)SPINK5base<http://bioinf.uta.fi/SPINK5base>SPINK5Netherton syndromeSTAT1base<http://bioinf.uta.fi/STAT1base>STAT1STAT1 deficiencySTAT3base<http://bioinf.uta.fi/STAT3base>STAT3Hyper-IgE syndromeSTAT5Bbase<http://bioinf.uta.fi/STAT5Bbase>STAT5BGrowth hormone insensitivity with immunodeficiencySTX11base<http://bioinf.uta.fi/STX11base>STX11Familial haemophagocytic lymphohistiocytosis 4TAP1base<http://bioinf.uta.fi/TAP1base>TAP1TAP1 deficiencyTAP2base<http://bioinf.uta.fi/TAP2base>TAP2TAP2 deficiencyTAPBPbase<http://bioinf.uta.fi/TAPBPbase>TAPBPTapasin deficiencyTAZbase<http://bioinf.uta.fi/TAZbase>TAZBarth syndromeTCIRG1base<http://bioinf.uta.fi/TCIRG1base>TCIRG1Autosomal recessive osteopetrosis (arOP)TCN2base<http://bioinf.uta.fi/TCN2base>TCN2Transcobalamin II deficiencyThe Cancer Genome Atlas (TCGA)<http://cancergenome.nih.gov/>\>400Brain (glioblastoma multiforme), ovarian (serous cystadenocarcinoma)Login for TCGA Data Portal necessary, more disease to comeTLR3base<http://bioinf.uta.fi/TLR3base>TLR3Influenza-associated encephalopathyTMC6base<http://bioinf.uta.fi/TMC6base>TMC6Epidermodysplasia verruciformisTMC8base<http://bioinf.uta.fi/TMC8base>TMC8Epidermodysplasia verruciformisTNFRSF13Bbase<http://bioinf.uta.fi/TNFRSF13Bbase>TNFRSF13BTACI deficiencyTYK2base<http://bioinf.uta.fi/TYK2base>TYK2TYK2 deficiencyUMD-ATP7B<http://www.umd.be/ATP7B/>ATPase, Cu++ transporting, beta polypetideWilson diseaseUMD-COL3A1<http://www.umd.be/COL3A1/>COL3A1COL3A1 deficiencyRestricted accessUMD-CSA<http://www.umd.be/CSA/>ERCC8ERCC8 deficiencyUMD-CSB<http://www.umd.be/CSB/>ERCC6ERCC6 deficiencyUMD-DFNB1-GJB2<http://www.umd.be/DFNB1-GJB2/>DFNB1, GJB2DFNB1 deficiencyRestricted accessUMD-DMD<http://www.umd.be/DMD/>DMDDMD deficiencyUMD-DPYD<http://www.umd.be/DPYD/>DPYDDihydropyrimidine dehydrogenase diseaseRestricted accessUMD-EMD<http://www.umd.be/EMD/>EMDEMD deficiencyUMD-FBN1<http://www.umd.be/FBN1/>FBN1Marfan syndrome and related disordersUMD-FBN2<http://194.167.35.168/FBN2/>FBN2Congenital contractural arachnodactylyUMD-LDLR<http://www.umd.be/LDLR/>LDLRFamilial hypercholesterolemia (FH)UMD-LMNA<http://www.umd.be/LMNA/>LMNALMNA deficiencyUMD-TGFBR1<http://www.umd.be/LSDB.html>TGFBR1TGFBR1 deficiencyRestricted accessUMD-TGFBR2<http://www.umd.be/TGFBR2/>TGFBR2Marfan syndrome, Loeys--Dietz syndome, Familial thoracic aortic anezrysms and dissectionsUMD-USHbases<http://www.umd.be/usher.html>Usher syndromeUNC13Dbase<http://bioinf.uta.fi/UNC13Dbase>UNC13DFamilial hemophagocytic lymphohistiocytosis 3UNC93B1base<http://bioinf.uta.fi/UNC93B1base>UNC93B1UNC93B deficiency (Herpes simplex encephalitis)UNGbase<http://bioinf.uta.fi/UNGbase>UNGUNG deficiencyWASbase<http://bioinf.uta.fi/WASbase>WASWiskott--Aldrich syndrome (WAS)WASPbase<http://homepage.mac.com/kohsukeimai/wasp/WASPbase.html>WASPWiskott--Aldrich syndromeZAP70base<http://bioinf.uta.fi/ZAP70base>ZAP70ZAP70 deficiency[^2]

Prominent disease mutation databases are the public *IDbases* ([@B53]) maintained at the Institute of Medical Technology, University of Tampere. The IDbases are LSDBs for immunodeficiency-causing mutations. The project maintains 122 different IDBases containing altogether data for 5359 patients. In addition to gene mutations, IDbases provide information about clinical presentation. All information has been collected from the literature as well as directly from researchers. The databases do not provide any sophisticated search interface and allow to download the data as a txt-file.

Conclusion
==========

All databases presented are good starting points to retrieve human variation data for certain use cases depending on the provided interfaces. However, as soon as a query gets more complicated, an integrative approach will be necessary. Unfortunately, the diversity of current mutation information systems and the underlying data models make it difficult to mine human variation databases in an integrative approach. Currently, researchers typically have to browse and search several databases to obtain the required information. No unified access to all different cancer genome related data sources exists resulting in a need for more efficient integrative systems. With COSMIC, which is currently integrating TCGA and IARC TP53 information, and the RCGDB, which already integrates most of in this review presented data sources, two promising integrative data resources are available. Nevertheless, the standardization and virtual consolidation of existing databases will be one major challenge for future developments. Although these problems have already been discussed in previous publications ([@B54; @B55; @B56]), the current situation concerning mutation databases and their heterogeneity is still an acute problem due to the exponential growth of data generated by genome sequencing. This review is meant to provide an overview on the current status of mutation data in public resources to overcome the difficulties for users to know where to find the information they are looking for.
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[^1]: For each database the type of mutations as well as the genes have been covered.

[^2]: For each database the disease as well as the genes have been covered.
